2. Academic Validation
  3. Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

  • J Med Chem. 2017 Dec 14;60(23):9769-9789. doi: 10.1021/acs.jmedchem.7b01236.
Olivier Bezençon 1,  Bibia Heidmann 1,  Romain Siegrist 1,  Simon Stamm 1,  Sylvia Richard 1,  Davide Pozzi 1,  Olivier Corminboeuf 1,  Catherine Roch 1,  Melanie Kessler 1,  Eric A Ertel 1,  Isabelle Reymond 1,  Thomas Pfeifer 1,  Ruben de Kanter 1,  Michael Toeroek-Schafroth 1,  Luca G Moccia 1,  Jacques Mawet 1,  Richard Moon 1,  Markus Rey 1,  Bruno Capeleto 1,  Elvire Fournier 1
Affiliations

Affiliation

  • 1 Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.
PMID: 29116786 DOI: 10.1021/acs.jmedchem.7b01236
Abstract

We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.

Figures
Products